(肿瘤生物学)Dual inhibition of MAGL and type II topoisomerase by Nphenylmaleimides as a potential strategy to reduce neuroblastoma cell growth.pdf

European Journal of Pharmaceutical Sciences 45 (2012) 263–271 Contents lists available at SciVerse ScienceDirect European Journal of Pharmaceutical Sciences journal homepage: /locate/ejps Dual inhibition of MAGL and type II topoisomerase by N-phenylmaleimides as a potential strategy to reduce neuroblastoma cell growth Nicolas Matuszak a, Laurie Hamtiaux a, Brigitte Baldeyroux c, Giulio G. Muccioli b, Jacques H. Poupaert a, Amélie Lansiaux c, Didier M. Lambert a,⇑ a Université catholique de Louvain, Louvain Drug Research Institute (LDRI), Medicinal Chemistry Research Group (CMFA), 73 avenue E. Mounier, bte B1.73.10, 1200 Bruxelles, Belgium b Université catholique de Louvain, Louvain Drug Research Institute (LDRI), Bioanalysis and Pharmacology of Bioactive Lipids Laboratory (BPBL), 72 avenue E. Mounier, bte B1.72.01, 1200 Bruxelles, Belgium c INSERM U-837, Centre Oscar Lambret, Université Lille Nord de France, Faculté de Médecine de Lille, IRCL, 59045 Lille, France a r t i c l e i n f o a b s t r a c t Article history: The endocannabinoid system is implicated in numerous physiopathological processes while more and Received 20 July 2011 more pieces of evidence wave the link between this complex machinery and cancer related phenomenon. Received in revised form 2 November 2011 In these lines, we confirmed the effects of 2-arachidonoylglycerol (2-AG), the main endocannabinoid, on Accepted 11 November 2011 neuroblastoma cells proliferation in vitro, and proved that some N-phenylmaleimide compounds that Available online 23 November 2011